PT2850106T - Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3 - Google Patents
Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3Info
- Publication number
- PT2850106T PT2850106T PT137902177T PT13790217T PT2850106T PT 2850106 T PT2850106 T PT 2850106T PT 137902177 T PT137902177 T PT 137902177T PT 13790217 T PT13790217 T PT 13790217T PT 2850106 T PT2850106 T PT 2850106T
- Authority
- PT
- Portugal
- Prior art keywords
- bif
- bispecific scfv
- immunofusion
- scfv immunofusion
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electronic Switches (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649211P | 2012-05-18 | 2012-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2850106T true PT2850106T (pt) | 2022-07-18 |
Family
ID=49584484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137902177T PT2850106T (pt) | 2012-05-18 | 2013-05-18 | Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9745381B2 (pt) |
| EP (2) | EP4053162A1 (pt) |
| ES (1) | ES2924722T3 (pt) |
| HU (1) | HUE059815T2 (pt) |
| PT (1) | PT2850106T (pt) |
| SM (1) | SMT202200295T1 (pt) |
| WO (1) | WO2013173820A2 (pt) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014518615A (ja) | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| SI2943511T1 (sl) | 2013-01-14 | 2020-01-31 | Xencor, Inc. | Novi heterodimerni proteini |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| EP3158064A1 (en) * | 2014-06-17 | 2017-04-26 | Cellectis | Cd123 specific multi-chain chimeric antigen receptor |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| RU2020117196A (ru) | 2014-08-19 | 2020-10-15 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| PT3189081T (pt) | 2014-09-05 | 2020-05-25 | Janssen Pharmaceutica Nv | Agentes de ligação a cd123 e seus usos |
| AU2015346205B2 (en) * | 2014-11-12 | 2021-07-29 | Memorial Sloan Kettering Cancer Center | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
| EP4183806A3 (en) | 2014-11-12 | 2023-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
| WO2016116626A1 (en) * | 2015-01-23 | 2016-07-28 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| AU2016257721B2 (en) * | 2015-05-01 | 2019-11-14 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
| WO2016179472A2 (en) * | 2015-05-07 | 2016-11-10 | University Of Maryland, Baltimore | Modulation of natural killer cell tolerance |
| MX2017017172A (es) | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
| US10744205B2 (en) * | 2015-06-23 | 2020-08-18 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies |
| TWI617319B (zh) * | 2015-09-01 | 2018-03-11 | 免疫功坊股份有限公司 | 用以治療病理性血栓的融合蛋白 |
| JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| SG11201801984TA (en) | 2015-10-01 | 2018-04-27 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| US20190000880A1 (en) | 2015-12-30 | 2019-01-03 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| PE20181852A1 (es) | 2016-03-24 | 2018-12-03 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles |
| EP3443096B1 (en) | 2016-04-15 | 2023-03-01 | Novartis AG | Compositions and methods for selective expression of chimeric antigen receptors |
| HUE068801T2 (hu) | 2016-06-14 | 2025-01-28 | Xencor Inc | Bispecifikus kontrollpont-gátló antitestek |
| CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| EP4050032A1 (en) | 2016-06-28 | 2022-08-31 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| EP3515491A4 (en) * | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCEDURES |
| CN110214152A (zh) * | 2016-10-14 | 2019-09-06 | 丹娜法伯癌症研究所公司 | 模块化四聚体双特异性抗体平台 |
| KR20240076829A (ko) * | 2016-11-16 | 2024-05-30 | 아블린쓰 엔.브이. | Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드 |
| WO2018094143A1 (en) * | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| WO2018114798A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
| CA3054130A1 (en) | 2017-02-27 | 2018-08-30 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| EP3585418A4 (en) | 2017-02-27 | 2020-11-25 | Shattuck Labs, Inc. | CHEMICAL PROTEINS FORMED FROM TIGIT AND LIGHT |
| SG11201906464UA (en) | 2017-02-27 | 2019-08-27 | Shattuck Labs Inc | Csf1r-based chimeric proteins |
| AR123115A1 (es) | 2017-10-18 | 2022-11-02 | Novartis Ag | Composiciones y métodos para la degradación selectiva de proteínas |
| WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| CA3165274A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| KR20230024967A (ko) | 2020-06-11 | 2023-02-21 | 노파르티스 아게 | Zbtb32 억제제 및 이의 용도 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| DK0826696T3 (da) * | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| NZ544924A (en) * | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| SG163615A1 (en) * | 2005-07-11 | 2010-08-30 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP3805269A1 (en) * | 2006-06-12 | 2021-04-14 | Aptevo Research and Development LLC | Single-chain multivalent binding proteins with effector function |
| CA2695382A1 (en) | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| EP4134095A1 (en) | 2009-09-15 | 2023-02-15 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| EP2637692A4 (en) | 2010-11-12 | 2014-09-10 | Scott & White Healthcare | ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8 |
-
2013
- 2013-05-18 PT PT137902177T patent/PT2850106T/pt unknown
- 2013-05-18 EP EP22163591.5A patent/EP4053162A1/en active Pending
- 2013-05-18 US US14/402,009 patent/US9745381B2/en active Active
- 2013-05-18 SM SM20220295T patent/SMT202200295T1/it unknown
- 2013-05-18 HU HUE13790217A patent/HUE059815T2/hu unknown
- 2013-05-18 ES ES13790217T patent/ES2924722T3/es active Active
- 2013-05-18 WO PCT/US2013/041739 patent/WO2013173820A2/en active Application Filing
- 2013-05-18 EP EP13790217.7A patent/EP2850106B1/en active Active
-
2017
- 2017-08-11 US US15/675,493 patent/US20180222996A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202200295T1 (it) | 2022-09-14 |
| US20150110789A1 (en) | 2015-04-23 |
| EP2850106A2 (en) | 2015-03-25 |
| WO2013173820A2 (en) | 2013-11-21 |
| EP4053162A1 (en) | 2022-09-07 |
| US9745381B2 (en) | 2017-08-29 |
| EP2850106A4 (en) | 2016-04-20 |
| HUE059815T2 (hu) | 2022-12-28 |
| ES2924722T3 (es) | 2022-10-10 |
| EP2850106B1 (en) | 2022-03-23 |
| US20180222996A1 (en) | 2018-08-09 |
| WO2013173820A3 (en) | 2014-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2850106A4 (en) | BISPÉCIFIC IMMUNOFUSION (IFB) OF SCFV | |
| HK1249530A1 (zh) | 靶組織特異性抗原結合分子 | |
| EP2922874A4 (en) | BISPECIFIC ANTIBODIES | |
| HK1201862A1 (en) | Anti-baff-anti-il-17 bispecific antibodies -baff--il-17 | |
| GB2508354B (en) | Communication method | |
| GB2508355B (en) | Communication method | |
| ZA201400624B (en) | Solids-handling equipment | |
| ZA201308491B (en) | Solids-handling equipment | |
| GB201202198D0 (en) | Method | |
| EP2881718A4 (en) | SPECTROMETER | |
| IL234712A0 (en) | A dual protocol for the communication of a self-contained femto application | |
| EP2841643A4 (en) | FORM FIELD | |
| GB201203337D0 (en) | Method | |
| GB201201332D0 (en) | Method | |
| GB2587577B (en) | Communication method | |
| EP2841644A4 (en) | TRAINING SECTION | |
| GB201220935D0 (en) | Method B | |
| GB201203796D0 (en) | Communications | |
| GB201202780D0 (en) | Communications | |
| GB201211321D0 (en) | Productive equipment | |
| PH32012000911S1 (en) | INTERLOCKING BLOCK (Ecoblock) | |
| GB201203012D0 (en) | Step 2gether | |
| GB201206745D0 (en) | N block | |
| GB201223358D0 (en) | Combines | |
| GB201223361D0 (en) | Combines |